GAD vaccine reduces insulin loss in recently diagnosed type 1 diabetes: findings from a Bayesian meta-analysis

Diabetologia

Volumn 60, Issue 1, 2017, Pages 43-49

  Beam, Craig A ^a   MacCallum, Colleen ^a   Herold, Kevan C ^b   Wherrett, Diane K ^c   Palmer, Jerry ^d   Ludvigsson, Johnny ^e  

^a WESTERN MICHIGAN UNIVERSITY HOMER STRYKER MD SCHOOL OF MEDICINE   (United States)

^b YALE UNIVERSITY   (United States)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^e LINKÖPING UNIVERSITY   (Sweden)

Author keywords

Bayes methods; Glutamic acid decarboxylase (GAD); Meta analysis; Type 1 diabetes; Vaccine

Indexed keywords

ALUMINUM POTASSIUM SULFATE; C PEPTIDE; GLUTAMATE DECARBOXYLASE 65; INSULIN; VACCINE; GLUTAMATE DECARBOXYLASE;

AREA UNDER THE CURVE; ARTICLE; BAYESIAN LEARNING; BIOLOGICAL ACTIVITY; HISTOGRAM; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; META ANALYSIS; PRIORITY JOURNAL; PROBABILITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; VACCINATION; ADOLESCENT; ADULT; BAYES THEOREM; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; BAYES THEOREM; CHILD; DIABETES MELLITUS, TYPE 1; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; INSULIN; MALE; MIDDLE AGED; VACCINES; YOUNG ADULT;

EID: 84990829763     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-4122-1     Document Type: Article

References (19)

1. Tian J, Kaufman DL (2009) Antigen-based therapy for the treatment of type 1 diabetes. Diabetes 58:1939–1946
2. Tian J, Clare-Salzler M, Herschenfeld A et al (1996) Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 2:1348–1353
3. Tisch R, Liblau RS, Yang XD, Liblau P, McDevitt HO (1998) Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 47:894–899
4. Ludvigsson J, Faresjo M, Hjorth M et al (2008) GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 359:1909–1920
5. Wherrett DK, Bundy B, Becker DJ et al (2011) Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 378:319–327
6. Ludvigsson J, Krisky D, Casas R et al (2012) GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 366:433–442
7. Wijeysundera DN, Austin PC, Hux JE, Beattie WS, Laupacis A (2009) Bayesian statistical inference enhances the interpretation of contemporary randomized controlled trials. J Clin Epidemiol 62(13–21), e15
8. Lee JJ (2011) Demystify statistical significance--time to move on from the p value to bayesian analysis. J Natl Cancer Inst 103:2–3
9. Lee JJ, Chu CT (2012) Bayesian clinical trials in action. Stat Med 31:2955–2972
10. Goodman S (2008) A dirty dozen: twelve p-value misconceptions. Semin Hematol 45:135–140
11. Skrivanek Z, Berry S, Berry D et al (2012) Application of adaptive design methodology in development of a long-acting glucagon-like peptide-1 analog (dulaglutide): statistical design and simulations. J Diabetes Sci Technol 6:1305–1318
12. Irie J, Reck B, Wu Y et al (2008) Genome-wide microarray expression analysis of CD4+ T cells from nonobese diabetic congenic mice identifies Cd55 (Daf1) and Acadl as candidate genes for type 1 diabetes. J Immunol 180:1071–1079
13. Argyropoulos C, Wang K, McClarty S, et al (2013) Erratum: Urinary microRNA profiling in the nephropathy of type 1 diabetes. PLoS one 8. doi: 10.1371/annotation/37e647d5-1781-4edf-86a8-e3b533c32ad9
14. Argyropoulos C, Wang K, McClarty S et al (2013) Urinary microRNA profiling in the nephropathy of type 1 diabetes. PLoS One 8, e54662
15. Emami A, Rabasa-Lhoret R, Haidar A (2015) Enhancing glucose sensor models: modeling the drop-outs. Diabetes Technol Ther 17:420–426
16. Greenbaum CJ, Beam CA, Boulware D et al (2012) Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite type 1 diabetes TrialNet data. Diabetes 61:2066–2073
17. Kuhtreiber WM, Washer SL, Hsu E et al (2015) Low levels of C-peptide have clinical significance for established type 1 diabetes. Diabet Med: J Br Diab Assoc 32:1346–1353
18. Sjoberg S, Gjotterberg M, Berglund L, Moller E, Ostman J (1991) Residual C-peptide excretion is associated with a better long-term glycemic control and slower progress of retinopathy in type I (insulin-dependent) diabetes mellitus. J Diabet Complications 5:18–22
19. Luppi P, Cifarelli V, Wahren J (2011) C-peptide and long-term complications of diabetes. Pediatr Diabetes 12:276–292